Related Experiment Video

Updated: Jul 12, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K

Positioning SUMO as an immunological facilitator of oncolytic viruses for high-grade glioma

Paramesh V Karandikar1,2, Lyle Suh1, Jakob V E Gerstl2

  • 1T. H. Chan School of Medicine, University of Massachusetts, Worcester, MA, United States.

Frontiers in Cell and Developmental Biology
|October 20, 2023
PubMed

Insights

Oncolytic viral (OV) therapies show promise for brain cancers. Targeting the SUMO pathway could enhance OV efficacy and overcome immune challenges in the central nervous system (CNS).

Area of Science:

  • Neuro-oncology
  • Virology
  • Immunology

Background:

  • Oncolytic viral (OV) therapies offer novel treatment options for central nervous system (CNS) cancers like glioblastoma.
  • Current OV efficacy in the CNS is limited by delivery issues, immune responses, and the
  • immune-cold
  • tumor microenvironment.

Purpose of the Study:

  • To explore the potential of SUMO (Small Ubiquitin-like Modifier) pathway modulation as an adjuvant therapy for enhancing OV efficacy in CNS malignancies.
  • To review the role of the SUMO pathway in CNS cancer pathogenesis and viral infections.

Main Methods:

  • Literature review of the SUMO pathway's role in CNS malignancies.
  • Overview of current central nervous system-targeted oncolytic viruses.
  • Analysis of the interplay between the SUMO pathway, viral lifecycle, and host immune response.

Main Results:

  • The SUMO pathway regulates key physiological processes, including immune responses, and is implicated in CNS cancer development.
  • SUMOtherapeutics present an interesting strategy to improve OV performance and overcome immune resistance in brain tumors.
  • Understanding the SUMO-viral-immune axis is crucial for optimizing OV-based cancer immunotherapies.

Conclusions:

  • The SUMO pathway is a critical regulator in CNS malignancies and viral infections.
  • Targeting the SUMO pathway offers a promising avenue for enhancing oncolytic virotherapy efficacy in the CNS.
  • SUMOtherapeutics, alone or with other immunotherapies, could revolutionize brain cancer treatment.
Keywords:
SUMOSUMOtherapeuticscancer immunotherapieshigh-grade gliomaoncolytic viruses

More Related Videos

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.0K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.5K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
538
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
383
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
933
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.1K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K